We are pleased to announce that the Translational Lung Cancer Research (TLCR) has attained its latest impact factor update for the 2023 citation year: 4 (Figure 1).
Figure 1. Journal Impact Factor of TLCR
Translational Lung Cancer Research (TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central. TLCR is dedicated to focus on cutting-edge developments at the transition from preclinical to clinical research and thus closes the gap between “bench and bedside”. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer and related thoracic diseases. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases. It is published quarterly (Mar. 2012 - Jan. 2013), bimonthly (Feb. 2013 - Dec. 2020), monthly (Jan. 2021 -) and openly distributed worldwide.
We strive to follow the best practices in publishing. The announcement of the journal’s latest impact factor is not only a significant achievement for the journal but also the recognition of its more significant scientific reach. Here, we would like to extend our heartfelt gratitude to all our Editorial Team Members, Guest Editors, authors, and reviewers for their significant contributions.
We look forward to the continuous cooperation with all the individuals mentioned above and those who are interested in lung cancer research to bring more exciting content to readers in the coming future.
Editorial Office
Translational Lung Cancer Research
June 20, 2024